Dendritic cell vaccination and immunostimulation in advanced melanoma

Expert Review of Vaccines

Volumn 2, Issue 6, 2003, Pages 825-833

  Ridolfi, Ruggero ^a   Ridolfi, Laura ^a   Petrini, Massimiliano ^b   Fiammenghi, Laura ^b   Riccobon, Angela ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

Advanced melanoma; Antigen presenting cell; Dendritic cell; Tumor immune escape; Tumor infiltrating lymphocyte; Tumor vaccination; Tumor associated antigen

Indexed keywords

B7 ANTIGEN; BCG VACCINE; CD209 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FAS LIGAND; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 12; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MELAN A; MELANOMA ANTIGEN 1; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; OSTEOCLAST DIFFERENTIATION FACTOR; T6 ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ANTIGEN PRESENTING CELL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MEMORY CELL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR ESCAPE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; MELANOMA; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0348110376     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.6.825     Document Type: Review

References (96)

1. Old LJ. Immunotherapy for cancer. Sci. Am. 275, 136-143 (1996).
2. Parmiani G. Future perspectives in specific immunotherapy of melanoma. Eur. J. Cancer 34(Suppl. 3), 42-47 (1998).
3. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729 (1996). One of the first works on the modalities of tumor antigen recognition.
4. Minev BR. Melanoma vaccines. Semin. Oncol. 29, 479-493 (2002).
5. Nestle FO. Vaccines and melanoma. Clin. Exp. Dermatol. 27, 597-601 (2002). Clarifies the possibilities of vaccination in melanoma.
6. Nelson J. Cancer vaccines, disappointing in the past, show promise. J. Natl Cancer Inst. 88, 486-488 (1996).
7. Soong TW, Hui KM. Locus-specific transcriptional control of HLA genes. J. Immunol. 149, 2008-2020 (1992).
8. Lanzavecchia A. Identifying strategies for immune intervention. Science 260, 937-944 (1993). Work that represents an important basis for modern immunology.
9. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin. Oncol 30, 23-29 (2003).
10. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000). Important revision of tumor immunoescape.
11. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am. J. Pathol. 154, 745-754 (1999).
12. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today. 5, 178-186 (1999).
13. Hicklin DJ, Wang Z, Arienti F et al. β2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest. 101, 2720-2729 (1998).
14. Hiby SE, King A, Sharkey A, Loke YW. Molecular studies of trophoblast HLA-G: polymorphism, isoforms, imprinting and expression in preimplantation embryo. Tissue Antigens 53, 1-13 (1999).
15. Clark DA, Chaouat G, Gorczynski RM. Thinking outside the box: mechanism of environmental selective pressures on the outcome of the materno-fetal relationship. Am. J. Reprod. Immunol 47, 275-282 (2002).
16. Solier C, Aguerre-Girr M, Lenfant F et al. Secretion of proapoptotic intron 4-retaining solubile HLA-G by human villous trophoblast. Eur. J. Immunol. 32, 3576-3586 (2002).
17. Geertsen R, Hofbauer G, Kamarashen J, Yue FY, Dummer R. Immune escape mechanisms in malignant melanoma. Int. J. Mol. Med. 3, 49-57 (1999).
18. Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal trasduction of T cells in cancer: the promise of cytokme gene therapy. Immunol. Today 1, 39-45 (1996). One of the first works on lymphocyte inactivation.
19. Whiteside TL, Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother. 46, 175-184 (1998). One of the first works to sustain the theory of Fas-L-induced immunosuppression.
20. De Paola F, Ridolfi R, Riccobon A et al. Restored T-cell activation mechanisms in human tumour-infiltration lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2. Br. J. Cancer 88, 320-325 (2003). This work confirms data on TIL inactivation in a clinical case series
21. + peripheral blood T lymphocytes of patients with melanoma. Clin. Cancer Res. 7(Suppl. 3), 947-957 (2001).
22. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat. Med. 7, 271-274 (2001). Important report on the role of FAS-L in tumor immunosuppression.
23. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. 151, 2390-2398 (1993).
24. Nagy N, Vanky F. Transforming growth factor β (TGFβ) secreted by immunogenic ex vivo human carcinoma cells, counteracts the activation and inhibits the function of autologous cytotoxic lymphocytes. Pretreatment with interferon gamma and tumor necrosis factor alpha reduces the production of active TGFβ. Cancer Immunol. Immunother. 45, 306-312 (1998).
25. Gabrilovic DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103 (1996).
26. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392, 245-253 (1998). One of the first works on the role of DCs.
27. Foss FM. Immunologic mechanisms of antitumor activity. Semin. Oncol. 29 (Suppl 7), 5-11 (2002).
28. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 106, 263-266 (2001). Update on immune regulation by DCs.
29. Maldonado-Lopez R, Moser M. Dendritic cell subsets and regulation of Th1/Th2 responses. Semin. Imnmnol. 13, 275-282 (2001).
30. Munn DH. Tolerogenic antigen-presenting cells. Ann. NY Acad. Sci. 961, 343-345 (2002).
31. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff B. J. Human sunlight-induced basall-cell-carcinoma-associated dendritic cells are deficient in T cell costimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol. 150, 641-651 (1997).
32. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94, 459-473 (2001). Interesting review, with a detailed description of some specific features regarding the use of DCs.
33. Lotze MT, Shurin M, Davis I, Amoscato A, Storkus WJ. Dendritic cell based therapy of cancer. Adv. Exp. Med. Biol. 417, 551-569 (1997).
34. Steinman RM, Adams JC, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organ of mice. IV. Identification and distribution in mouse spleen. J. Exp. Med. 141, 804-820 (1975). Historical work on the identification of DCs.
35. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001). Landmark study on the properties of DCs.
36. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr. Opin. Immunol. 13, 2291-2298 (2001).
37. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64 (2001). Important work on the function of cross-presentation.
38. Sallusto F, Lanzavecchia A. Mobilizing dendritic cells for tolerance, priming and chronic inflammation. J. Exp. Med. 189, 611-614 (1999).
39. Scheffer SR, Nave H, Korangy F et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer 103, 205-211 (2003).
40. Tada Y, O-Wang J, Takiguchi Y et al. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J. Immunol. 169, 2241-2245 (2002)
41. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101, 4485-4491 (2003).
42. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90, 3245-3287 (1997).
43. Herbst B, Lindemann A. Dendritic Cells for immunotherapy. Biomedical Progress 11, 1-6 (1998).
44. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. 18, 245-273 (2000)
45. De Vries IJ, Eggert AA, Scharenborg NM et al. Phenotypical and functional characterization of clinical grade dendritic ceflls. J. Immunol. 25, 429-438 (2002). Work on the phenotypical and functional characteristics of iDCs and mDCs.
46. Reinhard G, Marten A, Kiske SM, Fed F, Beiber T, Schmidt-Wolf IG. Generation of dendritic cell-based vaccines for cancer. Br. J. Cancer 86, 1529-1533 (2002).
47. Matzinger P. Tolerance, danger and the extended family. Annu. Rev. Imnmnol. 12, 991-1045 (1994).
48. Romani N, Ratzinger G, Pfaller K et al. Migration of dendritic cells into lymphatics. The Langerhans cell example: routes, regulation and relevance. Int. Rev. Cytol. 207, 237-270 (2001). Important update on DC migration.
49. Randolph GJ. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin. Immunol. 13, 267-74 (2001).
50. Caux C, Vanberviiet B, Massacrier C et al. Regulation of dendritic cell recruitment by chemokines. Transplantation 73(Suppl. 1), 7-11 (2002).
51. Saas P, Tiberghien P. Dendritic cells: to where do they lead? Transplantation 73(Suppl. 1), 12-15 (2002).
52. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsivness under steady state conditions in vivo. J. Exp. Med. 194, 769-780 (2001).
53. Carbone JE, Ohm DP. Immune dysfunction in cancer patients. Oncology (Huntingt) 16, 7-9 (2002).
54. Vicari AP, Caux C, Trincheri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12, 33-42 (2002).
55. + T cells. J. Immunol. 170, 1822-1829 (2003).
56. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 659-660 (1999). Landmark study of T-cell memory.
57. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109, 1519-1526 (2002). Report on the use of DCs in vaccines.
58. Schuler G, Schuler-Turner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147 (2003).
59. Gunzer M, Grabbe S. Dendritic cells in cancer immunotherapy. Crit. Rev. Immunol. 21, 133-145 (2001).
60. Brossart P, Wirths S, Brigger W, Kanz L. Dendritic cells in cancer vaccines. Exp. Hematol. 29, 1247-1255 (2001).
61. Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst. 94, 805-818 (2002).
62. Sprinzl GM, Kacani L, Schrott-Fischer A, Romani N, Thumfart WF. Dendritic cell vaccines for cancer therapy. Cancer Treat. Rev. 27, 247-255 (2001).
63. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258-261 (1992).
64. Santini SM, Lapenta C, Logozzi M et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 251, 204-207 (2000).
65. Thurnher M, Zelle-Rieser C, Ramoner R, Bartsch G, Holtl L. The disabled dendritic cell. FASEB J. 15, 1054-1061 (2001).
66. Blocklet D, Toungouz M, Kiss R et al. Inoxine and 99mTc-HMPAO labelling of antigen loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur. J. Nucl. Med. Mol. Imaging 30, 440-447 (2003).
67. Riccobon A, Ridolfi R, Fiorentini G et al. Dendritic cell vaccination in patients with melanoma and renal carcinoma: evaluation of radiolabeled immature and mature DC in vivo migration. Proc. Am. Soc. Clin. Oncol. 22, 167 Abstract 670 (2003).
68. De Vries JM, Krooshoop DJEB, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63, 12-17 (2003). Interesting work on the migration of iDCs and mDCs in vivo.
69. Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. 25, 97-138 (2002). Important report on the modalities for verifying the efficacy of vaccines in vivo and in vitro.
70. McCutcheon M, Wehner N, Wensky A et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Methods 210, 149-166 (1997).
71. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
72. Sallusto F, Calla M, Danidi C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182, 389-400 (1995).
73. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. 9, 641-649 (2003). Recent work on the method of evaluation of in vitro vaccine efficacy
74. Westermann J, Korner IJ, Kopp J et al. Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence of phenotype and functional properties. Cancer Immunol. Immunother. 52, 194-198 (2003).
75. Thumann P, Moc I, Hurnrich J, et al. Antigen loading of dendritic cells with whole tumor cell preparations. J. Immunol. Methods 277, 1-16 (2003).
76. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998). The first clinical work published on the use of DC vaccines in melanoma.
77. Nestle FO, Banchereau J, Harr D. Dendritic cells: on the move from bench to bedside. Nat. Med. 7, 761-765 (2001).
78. Schadendorf D, Nestle FO. Autologous dendritic cells for treatment of advanced cancer - an update. Recent Results Cancer Res. 158, 236-248 (2001).
79. + progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458 (2001).
80. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte derived dendritic cells expands specific T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669-1678 (1999).
81. + hematopoietic progenitor cells. Int. J. Cancer 86, 385-392 (2000).
82. Panelli MC, Wunderlich J, Jeffries J et al. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 23, 487-498 (2000).
83. + melanoma patients with Mage-3 or melan A peptide-pulsed antologous peripheral blood mononuclear cells plus recombinant human interleukin-12. Clin. Cancer Res. 7, 895-901 (2001).
84. Chang AE, Redman BG, Whitfield ER et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8, 1021-1032 (2002).
85. O'Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 52, 387-395 (2003).
86. McIlroy D, Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol. Immunother. Epub ahead of print (2003). First overall evaluation of 10 trials published in the literature.
87. Gilliet M, Kleinhans M, Lantelme E et al. Intranodal injection of seminature monocyte-derived dendritic cells induces T helper type I responses to protein neoantigen. Blood 102, 36-42 (2003).
88. Smithers M, O'Connell K, MacFadyen S et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol. Immunother. 52, 41-52 (2003).
89. Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J. Immunother. 26, 107-116 (2003).
90. Stift A, Friedl J, Dubsky P et al. Dendritic cell-based vaccination in solid cancer. J. Clin. Oncol. 21, 135-142 (2003). Review of the possibilities of clinical DC vaccination in different tumor types.
91. Ridolfi R. Cellular therapy: dendritic cell vaccination. Tumori 2 (Suppl 2), 54-56 (2003).
92. Hold L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8, 3369-3376 (2002).
93. Chapman PB. Vaccinating patients with autologous tumor. J. Clin. Oncol. 20, 4139-4140 (2002).
94. Wolchok JD, Livingston PO. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol. 2, 205-511 (2001).
95. Forni G, Lollini PL, Musiani P, Colombo MP. Immunoprevention of cancer: is the time ripe? Cancer Res. 60, 2571-2575 (2000).
96. Finn O, Forni G. Prophylactic cancer vaccines. Curr. Opinion Immunol. 14, 172-177 (2002).